Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: A study from the Fondazione Italiana Linfomi (FIL) Phase III MCL0208 trial

Documenti analoghi

• Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)‐MCL0208 clinical trial
  di: Francesca Cordero, et al.
  Pubblicazione: (2026)
• Long‐term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients
  di: Rita Tavarozzi, et al.
  Pubblicazione: (2025)
• Comparative Effectiveness of R‐miniCOMP Versus R‐miniCHOP in Older Non‐Fit Patients With Diffuse Large B‐Cell Lymphoma: Insights From a “Fondazione Italiana Linfomi” Cohort Study
  di: Alberto Bavieri, et al.
  Pubblicazione: (2025)
• Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
  di: Simone Ferrero, et al.
  Pubblicazione: (2025)
• 265 | IMPACT OF IGHV REPERTOIRE AFTER IBRUTINIB‐CONTAINING REGIMENS IN YOUNGER UNTREATED MCL PATIENTS: AN ANALYSIS OF THE TRIANGLE DATA EMBEDDED IN THE MULTIPLY PROJECT
  di: S. Ragaini, et al.
  Pubblicazione: (2025)